KRISTI Hawley
- Type
- Physician · Allopathic & Osteopathic Physicians / Dermatology
- Where
- CALEDONIA, MI
- NPI
- 1821350745
- Received
- $2,242,335 in 3,439 records, 2019 to 2025 ($2,195,096 general, $47,239 research)
- As principal investigator
- $308,340 of research payments to others in 55 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 508 | $344,377 |
| 2025 | Research payment | 5 | $25,577 |
| 2024 | General payment | 595 | $418,907 |
| 2024 | Research payment | 2 | $11,332 |
| 2023 | General payment | 584 | $393,381 |
| 2023 | Research payment | 4 | $9,676 |
| 2022 | General payment | 470 | $287,503 |
| 2022 | Research payment | 1 | $653 |
| 2021 | General payment | 402 | $201,183 |
| 2020 | General payment | 336 | $201,912 |
| 2019 | General payment | 532 | $347,829 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 536 | $1,635,873 |
| Consulting Fee | 73 | $241,303 |
| Travel and Lodging | 689 | $224,640 |
| Food and Beverage | 2,097 | $65,867 |
| Research payment | 12 | $47,239 |
| Honoraria | 9 | $17,608 |
| Compensation for serving as faculty or as a speaker for a medical education program | 1 | $4,840 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 1 | $3,680 |
| Education | 21 | $1,283 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-23 | Incyte Corporation | $7,335 | Consulting Fee | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-23 | Incyte Corporation | $3,375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-23 | Incyte Corporation | $3,260 | Consulting Fee | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-19 | Arcutis Biotherapeutics, Inc. | $146 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-12-18 | Galderma Laboratories, L.P. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-18 | UCB, Inc. | $683 | Travel and Lodging | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-18 | UCB, Inc. | $97 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-18 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-12-18 | Galderma Laboratories, L.P. | $5 | Food and Beverage | In-kind items and services | AKLIEF Drug, ACNE | 2025 | |
| 2025-12-17 | Galderma Laboratories, L.P. | $5 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-16 | Incyte Corporation | $67 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-16 | Incyte Corporation | $28 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-16 | Incyte Corporation | $12 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-15 | LEO Pharma Inc. | $17 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-12-12 | Arcutis Biotherapeutics, Inc. | $5,625 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-12-12 | UCB, Inc. | $5,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-12 | Arcutis Biotherapeutics, Inc. | $207 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-12-12 | UCB, Inc. | $14 | Food and Beverage | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-12 | Arcutis Biotherapeutics, Inc. | $13 | Food and Beverage | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-12-12 | Arcutis Biotherapeutics, Inc. | $10 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-12-11 | GENZYME CORPORATION | $5,551 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-11 | GENZYME CORPORATION | $146 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-11 | GENZYME CORPORATION | $49 | Travel and Lodging | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-10 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-10 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-09 | Arcutis Biotherapeutics, Inc. | $4,875 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-12-09 | Arcutis Biotherapeutics, Inc. | $6 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-12-08 | UCB, Inc. | $36 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-05 | PFIZER INC. | $5,350 | Consulting Fee | Cash or cash equivalent | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-12-05 | PFIZER INC. | $100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-12-04 | SANOFI US SERVICES INC. | $5,206 | Research payment | Cash or cash equivalent | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneo | 2025 | |
| 2025-12-04 | Kowa Pharmaceuticals America, Inc. | $4,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-12-04 | Kowa Pharmaceuticals America, Inc. | $3,375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-12-04 | ABBVIE INC. | $2,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-04 | Incyte Corporation | $83 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-04 | Kowa Pharmaceuticals America, Inc. | $27 | Travel and Lodging | Cash or cash equivalent | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-12-04 | Incyte Corporation | $20 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-04 | Incyte Corporation | $19 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-04 | Incyte Corporation | $10 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-03 | Incyte Corporation | $805 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-03 | Incyte Corporation | $438 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-03 | Incyte Corporation | $125 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-03 | Incyte Corporation | $61 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-12-03 | Galderma Laboratories, L.P. | $58 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-03 | Incyte Corporation | $38 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-12-03 | Incyte Corporation | $17 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-03 | Galderma Laboratories, L.P. | $17 | Travel and Lodging | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-03 | Incyte Corporation | $16 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-03 | Galderma Laboratories, L.P. | $12 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-03 | Galderma Laboratories, L.P. | $10 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-01 | SUN PHARMACEUTICAL INDUSTRIES INC. | $112 | Travel and Lodging | Cash or cash equivalent | ILUMYA Biological, Dermatology | 2025 | |
| 2025-12-01 | ABBVIE INC. | $31 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-01 | GENZYME CORPORATION | $9 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-26 | Galderma Laboratories, L.P. | $4,680 | Consulting Fee | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-25 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-11-24 | GENZYME CORPORATION | $20 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-24 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2025 | |
| 2025-11-22 | Galderma Laboratories, L.P. | $47 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-22 | Galderma Laboratories, L.P. | $21 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-22 | Galderma Laboratories, L.P. | $8 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-21 | Galderma Laboratories, L.P. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-21 | Galderma Laboratories, L.P. | $727 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-21 | Galderma Laboratories, L.P. | $187 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-21 | Galderma Laboratories, L.P. | $180 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-20 | UCB, Inc. | $5,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-20 | GENZYME CORPORATION | $4,697 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-20 | Incyte Corporation | $3,375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-20 | UCB, Inc. | $187 | Travel and Lodging | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-20 | GENZYME CORPORATION | $78 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-20 | GENZYME CORPORATION | $31 | Travel and Lodging | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-19 | Kowa Pharmaceuticals America, Inc. | $105 | Food and Beverage | In-kind items and services | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-11-18 | UCB, Inc. | $1,430 | Travel and Lodging | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-18 | UCB, Inc. | $125 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-18 | Galderma Laboratories, L.P. | $5 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-17 | Arcutis Biotherapeutics, Inc. | $1,500 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-17 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-17 | GENZYME CORPORATION | $8 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-13 | UCB, Inc. | $2,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-13 | Galderma Laboratories, L.P. | $17 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-13 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-12 | UCB, Inc. | $20 | Travel and Lodging | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-11 | Kowa Pharmaceuticals America, Inc. | $1,719 | Travel and Lodging | In-kind items and services | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-11-11 | Kowa Pharmaceuticals America, Inc. | $124 | Food and Beverage | In-kind items and services | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-11-11 | SUN PHARMACEUTICAL INDUSTRIES INC. | $22 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-11-11 | PFIZER INC. | $22 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2025 | |
| 2025-11-11 | Kowa Pharmaceuticals America, Inc. | $12 | Travel and Lodging | In-kind items and services | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-11-10 | Incyte Corporation | $28 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-11-06 | UCB, Inc. | $17 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-05 | Incyte Corporation | $1,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-05 | Incyte Corporation | $754 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-05 | Incyte Corporation | $29 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-03 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-11-03 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-31 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-10-30 | GENZYME CORPORATION | $10 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-29 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4,840 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | ILUMYA Biological, Dermatology | 2025 | |
| 2025-10-29 | Incyte Corporation | $3,375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-29 | SUN PHARMACEUTICAL INDUSTRIES INC. | $56 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-10-29 | Galderma Laboratories, L.P. | $8 | Food and Beverage | In-kind items and services | AKLIEF Drug, ACNE | 2025 | |
| 2025-10-28 | GENZYME CORPORATION | $5,551 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-28 | GENZYME CORPORATION | $61 | Travel and Lodging | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-28 | GENZYME CORPORATION | $42 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-28 | MAYNE PHARMA COMMERCIAL LLC | $18 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-28 | Galderma Laboratories, L.P. | $14 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-27 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-25 | LEO Pharma Inc. | $112 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-10-25 | GENZYME CORPORATION | $89 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-25 | Novartis Pharmaceuticals Corporation | $62 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-10-25 | Incyte Corporation | $45 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-10-24 | Galderma Laboratories, L.P. | $131 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-24 | E.R. Squibb & Sons, L.L.C. | $29 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-10-24 | Incyte Corporation | $25 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-10-23 | GENZYME CORPORATION | $30 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-23 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-23 | Novartis Pharmaceuticals Corporation | $5 | Food and Beverage | In-kind items and services | XOLAIR Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-10-22 | Incyte Corporation | $92 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-22 | Incyte Corporation | $28 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-22 | Incyte Corporation | $12 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-21 | Arcutis Biotherapeutics, Inc. | $1 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-10-20 | UCB, Inc. | $25 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-10-20 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-10-16 | Kowa Pharmaceuticals America, Inc. | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-10-16 | Incyte Corporation | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-14 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-10-13 | Regeneron Healthcare Solutions, Inc. | $33 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-13 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2025 | |
| 2025-10-13 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-08 | SANOFI US SERVICES INC. | $3,951 | Research payment | Cash or cash equivalent | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneo | 2025 | |
| 2025-10-08 | ABBVIE INC. | $2,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-07 | PFIZER INC. | $4,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | 2025 | |
| 2025-10-06 | PFIZER INC. | $4,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | 2025 | |
| 2025-10-06 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,400 | Consulting Fee | Cash or cash equivalent | ILUMYA Biological, Dermatology | 2025 | |
| 2025-10-02 | Incyte Corporation | $3,000 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-30 | Arcutis Biotherapeutics, Inc. | $6,375 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-30 | Arcutis Biotherapeutics, Inc. | $3,375 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-30 | Organon Llc | $24 | Food and Beverage | In-kind items and services | NEXPLANON Drug, ETONOGESTREL | 2025 | |
| 2025-09-30 | Janssen Biotech, Inc. | $21 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-30 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-09-29 | GENZYME CORPORATION | $11 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-28 | Arcutis Biotherapeutics, Inc. | $80 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-28 | Arcutis Biotherapeutics, Inc. | $24 | Food and Beverage | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-28 | Arcutis Biotherapeutics, Inc. | $10 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-26 | Novartis Pharmaceuticals Corporation | $402 | Travel and Lodging | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-09-26 | Novartis Pharmaceuticals Corporation | $219 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-09-26 | Novartis Pharmaceuticals Corporation | $198 | Travel and Lodging | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-09-26 | Galderma Laboratories, L.P. | $4 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-09-25 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-09-23 | Novartis Pharmaceuticals Corporation | $13 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-09-22 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-09-19 | UCB, Inc. | $15 | Travel and Lodging | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-09-18 | Arcutis Biotherapeutics, Inc. | $1,364 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-18 | Arcutis Biotherapeutics, Inc. | $1,347 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-18 | Arcutis Biotherapeutics, Inc. | $159 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-18 | Arcutis Biotherapeutics, Inc. | $159 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-17 | SANOFI US SERVICES INC. | $2,048 | Research payment | Cash or cash equivalent | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneo | 2025 | |
| 2025-09-17 | Arcutis Biotherapeutics, Inc. | $1,134 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-17 | Arcutis Biotherapeutics, Inc. | $151 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-17 | Arcutis Biotherapeutics, Inc. | $151 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-17 | Arcutis Biotherapeutics, Inc. | $124 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-17 | Incyte Corporation | $94 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-09-17 | Incyte Corporation | $10 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-09-16 | Arcutis Biotherapeutics, Inc. | $1,875 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-16 | SUN PHARMACEUTICAL INDUSTRIES INC. | $90 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-09-15 | Arcutis Biotherapeutics, Inc. | $12 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-10 | Galderma Laboratories, L.P. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-09-04 | GENZYME CORPORATION | $30 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-04 | Galderma Laboratories, L.P. | $13 | Food and Beverage | In-kind items and services | DYSPORT Drug | 2025 | |
| 2025-09-03 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-03 | LEO Pharma Inc. | $20 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-09-03 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-09-03 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-09-03 | PFIZER INC. | $10 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2025 | |
| 2025-09-02 | Incyte Corporation | $15 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-09-02 | Janssen Biotech, Inc. | $11 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-29 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,400 | Consulting Fee | Cash or cash equivalent | ILUMYA Biological, Dermatology | 2025 | |
| 2025-08-29 | Galderma Laboratories, L.P. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-29 | Arcutis Biotherapeutics, Inc. | $179 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-29 | Arcutis Biotherapeutics, Inc. | $179 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-29 | Arcutis Biotherapeutics, Inc. | $124 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-29 | Arcutis Biotherapeutics, Inc. | $124 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-26 | Arcutis Biotherapeutics, Inc. | $17 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-20 | GENZYME CORPORATION | $1,921 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-18 | Novartis Pharmaceuticals Corporation | $29 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-08-18 | Novartis Pharmaceuticals Corporation | $29 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-08-18 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-08-15 | Regeneron Healthcare Solutions, Inc. | $37 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-14 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8 | Food and Beverage | In-kind items and services | Winlevi Drug, Dermatology | 2025 | |
| 2025-08-14 | Galderma Laboratories, L.P. | $6 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-12 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-11 | GENZYME CORPORATION | $11 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-07 | GENZYME CORPORATION | $2,989 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-07 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-07 | E.R. Squibb & Sons, L.L.C. | $12 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-08-06 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-05 | Incyte Corporation | $87 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-08-05 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-08-05 | LNHC, Inc | $18 | Food and Beverage | In-kind items and services | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-08-04 | UCB, Inc. | $30 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-04 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-08-01 | Galderma Laboratories, L.P. | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 |
The latest 200 records of 3,439.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-25 | Janssen Research & Development, LLC | DERM INSTITUTE OF WEST MICHIGAN PLC | $5,500 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-12-18 | SUN PHARMACEUTICAL INDUSTRIES INC. | DERM INSTITUTE OF WEST MICHIGAN PLC | $6,278 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Ps | 2025 |
| 2025-12-04 | ABBVIE INC. | DERM INSTITUTE OF WEST MICHIGAN | $4,124 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-11-19 | SANOFI US SERVICES INC. | The Derm Institute Of West Michigan Plc | $4,085 | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | 2025 |
| 2025-11-13 | SUN PHARMACEUTICAL INDUSTRIES INC. | DERM INSTITUTE OF WEST MICHIGAN PLC | $6,103 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Ps | 2025 |
| 2025-11-10 | Novartis Pharmaceuticals Corporation | THE DERM INSTITUTE OF WEST MICHIGAN, PLC | $523 | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared | 2025 |
| 2025-11-07 | SANOFI US SERVICES INC. | The Derm Institute Of West Michigan Plc | $195 | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | 2025 |
| 2025-10-27 | Janssen Research & Development, LLC | DERM INSTITUTE OF WEST MICHIGAN PLC | $2,288 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-10-24 | Janssen Research & Development, LLC | DERM INSTITUTE OF WEST MICHIGAN PLC | $1,960 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-10-23 | SUN PHARMACEUTICAL INDUSTRIES INC. | DERM INSTITUTE OF WEST MICHIGAN PLC | $15,189 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Ps | 2025 |
| 2025-10-09 | ABBVIE INC. | DERM INSTITUTE OF WEST MICHIGAN | $12,726 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-10-09 | SUN PHARMACEUTICAL INDUSTRIES INC. | DERM INSTITUTE OF WEST MICHIGAN PLC | $4,599 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Ps | 2025 |
| 2025-09-29 | Janssen Research & Development, LLC | DERM INSTITUTE OF WEST MICHIGAN PLC | $1,960 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-09-10 | SANOFI US SERVICES INC. | The Derm Institute Of West Michigan Plc | $195 | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | 2025 |
| 2025-09-08 | Janssen Research & Development, LLC | DERM INSTITUTE OF WEST MICHIGAN PLC | $4,716 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-08-13 | SUN PHARMACEUTICAL INDUSTRIES INC. | DERM INSTITUTE OF WEST MICHIGAN PLC | $8,004 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Ps | 2025 |
| 2025-08-12 | SUN PHARMACEUTICAL INDUSTRIES INC. | DERM INSTITUTE OF WEST MICHIGAN PLC | $13,177 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Ps | 2025 |
| 2025-07-31 | Janssen Research & Development, LLC | DERM INSTITUTE OF WEST MICHIGAN PLC | $6,393 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-07-28 | Janssen Research & Development, LLC | DERM INSTITUTE OF WEST MICHIGAN PLC | $2,779 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-07-11 | SANOFI US SERVICES INC. | The Derm Institute Of West Michigan Plc | $1,000 | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | 2025 |
| 2025-07-11 | SANOFI US SERVICES INC. | The Derm Institute Of West Michigan Plc | $3,415 | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | 2025 |
| 2025-07-02 | ABBVIE INC. | DERM INSTITUTE OF WEST MICHIGAN | $10,573 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-05-26 | Janssen Research & Development, LLC | DERM INSTITUTE OF WEST MICHIGAN PLC | $1,737 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-05-21 | SANOFI US SERVICES INC. | The Derm Institute Of West Michigan Plc | $390 | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | 2025 |
| 2025-05-13 | Eli Lilly and Company | THE DERM INSTITUTE OF WEST MICHIGAN | $15,526 | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEK | 2025 |
| 2025-05-07 | Eli Lilly and Company | THE DERM INSTITUTE OF WEST MICHIGAN | $31,290 | OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS | 2025 |
| 2025-04-11 | SANOFI US SERVICES INC. | The Derm Institute Of West Michigan Plc | $2,561 | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | 2025 |
| 2025-04-11 | Eli Lilly and Company | THE DERM INSTITUTE OF WEST MICHIGAN | $5,000 | PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCAL | 2025 |
| 2025-03-24 | Janssen Research & Development, LLC | DERM INSTITUTE OF WEST MICHIGAN PLC | $2,460 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-03-03 | Janssen Research & Development, LLC | DERM INSTITUTE OF WEST MICHIGAN PLC | $1,728 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-02-19 | SANOFI US SERVICES INC. | The Derm Institute Of West Michigan Plc | $1,178 | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | 2025 |
| 2025-01-28 | Eli Lilly and Company | THE DERM INSTITUTE OF WEST MICHIGAN | $50,454 | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH M | 2025 |
| 2025-01-27 | Janssen Research & Development, LLC | DERM INSTITUTE OF WEST MICHIGAN PLC | $4,624 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-01-27 | Eli Lilly and Company | THE DERM INSTITUTE OF WEST MICHIGAN | $2,790 | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH M | 2025 |
| 2025-01-15 | SANOFI US SERVICES INC. | The Derm Institute Of West Michigan Plc | $7,460 | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | 2025 |
| 2024-12-30 | Eli Lilly and Company | THE DERM INSTITUTE OF WEST MICHIGAN | $3,561 | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH M | 2024 |
| 2024-12-16 | Janssen Research & Development, LLC | DERM INSTITUTE OF WEST MICHIGAN PLC | $4,737 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2024 |
| 2024-10-28 | Janssen Research & Development, LLC | DERM INSTITUTE OF WEST MICHIGAN PLC | $2,164 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2024 |
| 2024-10-25 | SANOFI US SERVICES INC. | The Derm Institute Of West Michigan Plc | $3,415 | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | 2024 |
| 2024-10-25 | SANOFI US SERVICES INC. | The Derm Institute Of West Michigan Plc | $260 | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | 2024 |
| 2024-09-30 | Janssen Research & Development, LLC | DERM INSTITUTE OF WEST MICHIGAN PLC | $1,942 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2024 |
| 2024-09-03 | SANOFI US SERVICES INC. | The Derm Institute Of West Michigan Plc | $4,000 | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | 2024 |
| 2024-08-27 | Eli Lilly and Company | THE DERM INSTITUTE OF WEST MICHIGAN | $2,281 | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH M | 2024 |
| 2024-08-26 | Janssen Research & Development, LLC | DERM INSTITUTE OF WEST MICHIGAN PLC | $2,515 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2024 |
| 2024-08-14 | SANOFI US SERVICES INC. | The Derm Institute Of West Michigan Plc | $260 | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | 2024 |
| 2024-07-26 | SANOFI US SERVICES INC. | The Derm Institute Of West Michigan Plc | $7,670 | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | 2024 |
| 2024-07-26 | Janssen Research & Development, LLC | DERM INSTITUTE OF WEST MICHIGAN PLC | $16,944 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2024 |
| 2024-02-26 | Eli Lilly and Company | THE DERM INSTITUTE OF WEST MICHIGAN | $85 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEB | 2024 |
| 2024-01-19 | Eli Lilly and Company | THE DERM INSTITUTE OF WEST MICHIGAN | $7,529 | PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCAL | 2024 |
| 2023-11-02 | Eli Lilly and Company | THE DERM INSTITUTE OF WEST MICHIGAN | $2,792 | AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERA | 2023 |
| 2023-10-20 | Eli Lilly and Company | THE DERM INSTITUTE OF WEST MICHIGAN | $4,866 | PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED SINGLE-ARM PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF NAIL AND SCALP PS | 2023 |
| 2023-07-18 | Eli Lilly and Company | THE DERM INSTITUTE OF WEST MICHIGAN | $58 | A PHASE 3 MULTICENTER LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONT | 2023 |
| 2023-04-25 | Eli Lilly and Company | THE DERM INSTITUTE OF WEST MICHIGAN | $114 | A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO ASSESS THE EFFICACY SAFETY AND PHARMACOKINETICS OF LEBRIKI | 2023 |
| 2023-03-09 | Eli Lilly and Company | THE DERM INSTITUTE OF WEST MICHIGAN | $2 | AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERA | 2023 |
| 2022-12-31 | ABBVIE INC. | DERM INSTITUTE OF WEST MICHIGAN | $157 | A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Caledonia, MI, county Kent County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Caledonia, MI | County Kent County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 1,671 | 663,150 | 10,077,761 |
| Population, 2020 census P1 | 1,622 | 657,974 | 10,077,331 |
| Median age B01002 | 38.0 | 35.9 | 40.2 |
| Under 18 B01001 | 24.6% | 23.5% | 21.2% |
| 65 and over B01001 | 11.5% | 14.9% | 18.6% |
| Households B11001 | 651 | 256,648 | 4,076,369 |
| Foreign born B05002 | 5.2% | 8.9% | 7.2% |
| Median household income B19013 | $106,250 | $82,631 | $72,875 |
| Median family income B19113 | $121,513 | $102,163 | $93,357 |
| Per capita income B19301 | $48,421 | $42,992 | $40,735 |
| Poverty rate B17001 | 3.7% | 10.1% | 13.2% |
| Unemployment rate B23025 | 0.5% | 4.2% | 5.7% |
| Civilian labor force B23025 | 1,010 | 361,246 | 5,018,449 |
| Mean commute (minutes) B08013 | 21.5 | 21.0 | 24.2 |
| Bachelor's degree or higher B15003 | 54.4% | 40.8% | 32.4% |
| Housing units B25001 | 660 | 269,136 | 4,622,236 |
| Owner-occupied B25003 | 73.7% | 70.3% | 73.2% |
| Renters B25003 | 26.3% | 29.7% | 26.8% |
| Median home value B25077 | $339,000 | $289,900 | $231,600 |
| Median gross rent B25064 | $1,128 | $1,243 | $1,129 |
| White, not Hispanic B03002 | 87.4% | 70.4% | 72.4% |
| Black B03002 | 0.8% | 9.4% | 13.1% |
| Hispanic or Latino B03002 | 4.5% | 11.7% | 5.9% |
| Asian B03002 | 3.3% | 3.2% | 3.4% |
| American Indian and Alaska Native B03002 | 0.0% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Caledonia, MI.
Comments